Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Zurampic

×

Overview

What is Zurampic?

ZURAMPIC (lesinurad) is a URAT1 inhibitor. Lesinurad has the following chemical name: 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4-1,2,4-triazol-3-yl)thio)acetic acid. The molecular formula is CHBrNOS and the molecular weight is 404.28. The structural formula is:

ZURAMPIC is available as blue film-coated tablets for oral administration containing 200 mg lesinurad and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, hypromellose 2910, crospovidone, and magnesium stearate. ZURAMPIC tablets are coated with Opadry blue.



What does Zurampic look like?



What are the available doses of Zurampic?

Tablet: 200 mg.

What should I talk to my health care provider before I take Zurampic?

How should I use Zurampic?

ZURAMPIC is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone [s].

ZURAMPIC tablets are for oral use and should be co-administered with a xanthine oxidase inhibitor, including allopurinol or febuxostat.

ZURAMPIC is recommended at 200 mg once daily. This is also the maximum daily dose. ZURAMPIC should be taken by mouth, in the morning with food and water.

ZURAMPIC may be added when target serum uric acid levels are not achieved on the medically appropriate dose of the xanthine oxidase inhibitor alone.

Use of ZURAMPIC is not recommended for patients taking daily doses of allopurinol less than 300 mg (or less than 200 mg in patients with estimated creatinine clearance (eCLcr) less than 60 mL/min). Take ZURAMPIC at the same time as the morning dose of xanthine oxidase inhibitor. If treatment with the xanthine oxidase inhibitor is interrupted, ZURAMPIC should also be interrupted. Failure to follow these instructions may increase the risk of renal events [].

Patients should be instructed to stay well hydrated (e.g., 2 liters [68 oz] of liquid per day).


What interacts with Zurampic?

Sorry No Records found


What are the warnings of Zurampic?

Sorry No Records found


What are the precautions of Zurampic?

Sorry No Records found


What are the side effects of Zurampic?

Sorry No records found


What should I look out for while using Zurampic?

The use of ZURAMPIC is contraindicated in the following conditions:


What might happen if I take too much Zurampic?

ZURAMPIC was studied in healthy subjects given single doses up to 1600 mg without evidence of dose-limiting toxicities. In case of overdose patients should be managed by symptomatic and supportive care including adequate hydration.


How should I store and handle Zurampic?

Protect from light. Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [].Product: 71335-0433NDC: 71335-0433-2 30 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-3 60 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-4 90 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-1 100 TABLET, FILM COATED in a BOTTLEProduct: 71335-0433NDC: 71335-0433-2 30 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-3 60 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-4 90 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-1 100 TABLET, FILM COATED in a BOTTLEProduct: 71335-0433NDC: 71335-0433-2 30 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-3 60 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-4 90 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-1 100 TABLET, FILM COATED in a BOTTLEProduct: 71335-0433NDC: 71335-0433-2 30 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-3 60 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-4 90 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-1 100 TABLET, FILM COATED in a BOTTLEProduct: 71335-0433NDC: 71335-0433-2 30 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-3 60 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-4 90 TABLET, FILM COATED in a BOTTLENDC: 71335-0433-1 100 TABLET, FILM COATED in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. Lesinurad inhibited the function of two apical transporters responsible for uric acid reabsorption, uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4), with IC values of 7.3 and 3.7 µM, respectively. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. OAT4 is a uric acid transporter associated with diuretic-induced hyperuricemia. Lesinurad does not interact with the uric acid reabsorption transporter SLC2A9 (Glut9), located on the basolateral membrane of the proximal tubule cell.

Non-Clinical Toxicology
The use of ZURAMPIC is contraindicated in the following conditions:

Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy.

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. Their concurrent use should be avoided.

A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.

In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Ethacrynic acid and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Treatment with ZURAMPIC 200 mg in combination with a xanthine oxidase inhibitor was associated with an increased incidence of serum creatinine elevations, most of which were reversible []. Adverse reactions related to renal function have occurred after initiating ZURAMPIC. A higher incidence of serum creatinine elevations and renal-related adverse reactions, including serious adverse reactions of acute renal failure, was observed with ZURAMPIC 400 mg, with the highest incidence as monotherapy. ZURAMPIC should not be used as monotherapy [].

ZURAMPIC should not be initiated in patients with an eCLcr less than 45 mL/min. Renal function should be evaluated prior to initiation of ZURAMPIC and periodically thereafter, as clinically indicated. More frequent renal function monitoring is recommended in patients with an eCLcr less than 60 mL/min [] or with serum creatinine elevations 1.5 to 2 times the pre-treatment value. ZURAMPIC treatment should be interrupted if serum creatinine is elevated to greater than 2 times the pre-treatment value. In patients who report symptoms that may indicate acute uric acid nephropathy including flank pain, nausea or vomiting, interrupt treatment and measure serum creatinine promptly. ZURAMPIC should not be restarted without another explanation for the serum creatinine abnormalities.

The following adverse reactions are also discussed in other sections:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).